FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to drugs, and concerns combined antiaggregant and antioxidant containing acetylsalicylic acid as an active base, differing by the fact that the active base additionally contains Thiotriazoline.
EFFECT: combined drug exhibits more evident antiaggregant and antioxidant action and provides lower frequency rate of manifested undesired effects of prolonged pharmacotherapy.
2 cl, 1 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF ANTIPLATELET THERAPY EFFICIENCY REDUCTION RISK | 2016 |
|
RU2623051C1 |
| AGENT SHOWING ANTIAGGREGANT AND ANTITHROMBOGENIC ACTIVITY | 2010 |
|
RU2453312C1 |
| COMBINATION POSSESSING ANTIAGGREGANT, LIPID-REGULATING AND GASTROPROTECTIVE ACTIVITIES, PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2453314C1 |
| CARDIOPROTECTIVE, ANTIARRHYTHMIC ANTI-ISHEMIC AGENT | 2007 |
|
RU2366426C2 |
| METHOD OF DETERMINING ANTI-THROMBOTIC EFFECT OF ACETYLSALICYLIC ACID | 2007 |
|
RU2379684C2 |
| DICALCIUM SALT OF N-(3-HYDROXYBENZOYL)TAURINE, HAVING ANTIAGGREGANT AND ANTITHROMBOTIC ACTIVITY IN COMBINATION WITH CEREBROPROTECTIVE ACTION | 2019 |
|
RU2730835C1 |
| METHOD OF ASSESSING THE EFFICIENCY OF ANTI-CLEGGANT MEDICINAL PRODUCT IN WHOLE PERIPHERAL BLOOD SAMPLES | 2022 |
|
RU2800671C1 |
| DRUG PREPARATION POSSESSING ANTIAGGRREGANT ACTIVITY | 2011 |
|
RU2486182C2 |
| METHOD FOR CORRECTION OF DISTURBED FUNCTIONAL ACTIVITY OF PLATELETS | 2012 |
|
RU2497520C1 |
| 1-(3-MORPHOLINOPROPYL)-2-PHENYLIMIDAZO[1,2-a]-BENZIMIDAZOLE DIHYDROCHLORIDE, HAVING PURINE P2Y-RECEPTOR ANTAGONIST PROPERTIES, ANTIAGGREGANT AND ANTITHROMBOTIC ACTIVITY | 2008 |
|
RU2391345C2 |
